Lenvatinib Plus Pembrolizumab Safe, Effective in non-MSI-H/pMMR CRC
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).